key: cord-1012724-mesrgd6x authors: Roberts, Drucilla J.; Edlow, Andrea G.; Romero, Roberto J.; Coyne, Carolyn B.; Ting, David T.; Hornick, Jason L.; Zaki, Sherif R.; Adhikari, Upasana Das; Serghides, Lena; Gaw, Stephanie L.; Metz, Torri D. title: SPECIAL REPORT: A standardized definition of placental infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a consensus statement from the National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD) SARS-CoV-2 placental infection workshop date: 2021-08-05 journal: Am J Obstet Gynecol DOI: 10.1016/j.ajog.2021.07.029 sha: ca534899eaa1701217a5ee020913b6b8dbe01e95 doc_id: 1012724 cord_uid: mesrgd6x Pregnant individuals infected with SARS-CoV-2 have higher rates of ICU admission, oxygen requirement, need for mechanical ventilation and death than non-pregnant individuals. Increased COVID-19 disease severity may be associated with increased risk for viremia and placental infection. Maternal SARS-CoV-2 infection is also associated with pregnancy complications such as preeclampsia and preterm birth, that can be either placentally-mediated or reflected in the placenta. Maternal viremia followed by placental infection may lead to maternal-fetal transmission (vertical), which affects 1-3% of exposed newborns. However, there is no agreed-upon or standard definition of placental infection. NIH/NICHD convened a group of experts to propose a working definition of placental infection to inform ongoing studies of SARS-CoV-2 during pregnancy. Experts recommended that placental infection be defined using techniques that allow virus detection and localization in placental tissue by one or more of the following methods: in-situ hybridization with anti-sense probe (detects replication) and/or a sense probe (detects viral genome or immunohistochemistry to detect viral nucleocapsid (N) or spike (S) proteins. If the above methods are not possible, RT-PCR detection and/or quantification of viral RNA in placental homogenates, or electron microscopy are alternative approaches. A graded classification for the likelihood of placental infection as definitive, probable, possible, and unlikely was proposed. Manuscripts reporting placental infection should describe the sampling method (location and number of samples collected), method of preservation of tissue, and detection technique. Recommendations were made for the handling of the placenta, examination, and sampling, as well as the use of validated reagents and sample protocols (included as appendices). Introduction mechanical ventilation, extracorporeal membrane oxygenation, and death than non-pregnant individuals 1-3 but 88 the risk of placental, fetal, and pregnancy complications have been less well described. Studies show that 89 maternal SARS-CoV-2 infection is associated with an increased risk for preterm birth and preeclampsia 4-6 , both 90 of which may be placentally-mediated and/or placentally-reflected complications. Moreover, published reports 91 [7] [8] [9] show that first and second trimester infections with SARS-CoV-2 are possible and can result in pregnancy 92 loss. Recent reports from the United Kingdom also found second trimester miscarriage and stillbirth associated 93 with presumed placental SARS-CoV-2 infection, placentitis, and specifically the B.1.1.7 variant 10, 11 . These 94 reports suggest that placental infection does carry significant perinatal morbidity and that clinical surveillance 95 of exposed pregnancies and placental evaluation for infection are warranted. In addition, placental infection 96 does not equate with vertical transmission but may cause placental damage which leads to perinatal morbidity 97 without infection. Many have noted the triad of histiocytic intervillositis, increased perivillous fibrin deposition, 98 and trophoblast necrosis associated with placental infection 10, [12] [13] [14] [15] [16] [17] [18] [19] . Although these histologic findings are not 99 specific for infection, they are characteristic enough to indicate a study to evaluate if the placenta was infected. 100 101 While early reports were focused on SARS-CoV-2 placental infection and in utero transmission 19-26 , larger 102 studies and meta-analyses indicate that placental infection and vertical transmission were rare 4, 9, 27-32 , 103 particularly in comparison to other maternal viral infections in pregnancy (such as CMV, Zika, rubella, and 104 untreated HIV [33] [34] [35] [36] For RT-PCR testing we recommend at least two fresh placental samples (0.5 cm 3 ) taken within 20 minutes of 163 placental delivery (and not more than 1 hour past placental delivery to avoid RNA degradation), best obtained 164 in the delivery room by appropriately protected and trained individuals, from the fetal side of the placenta (see 165 Figures 1 and 2 ) rinsed in sterile normal saline or phosphate buffered saline, and then either snap frozen (in 166 liquid nitrogen or on dry ice until placed in -80°C) or placed in 5-10 volumes of RNALater (ThermoFisher 167 Scientific, Waltham MA) for subsequent freezing and storage at -80°C. Biopsies should be taken from a mid-168 point between the chorionic and basal plates, and midway between the cord insertion and the placental edge (at 169 least 3 cm from the cord insertion and 3 cm from the placental edge) to ensure viable villous parenchyma is 170 collected (Figures 1 and 2) . The fetal membranes should be dissected off the fetal surface and not included in 171 the biopsy. Two samples are recommended for protection against failure of RNA extraction and for biological 172 sampling diversity of different placental regions, agiven that patchy infection is possible 45 . Snap-frozen biopsies 173 may permit single-cell RNA-Seq/nuc-Seq approaches, other RNA analyses, and protein analyses, while biopsies 174 preserved in RNALater can be used for RNA/DNA analyses and protein analyses, but not for scRNA-seq/nuc-175 Seq. RNA quality is likely better for longer periods of time with the use of RNALater. For RNA in situ 176 hybridization and immunohistochemistry studies, formalin-fixed paraffin-embedded full thickness placental 177 parenchyma cut at 5 µm onto glass slides should be used. All studied placentas should be examined and 178 reported promptly by pathology following the Amsterdam Criteria for sampling and histological diagnoses. studies are more valuable when the studies utilize the same standardized methods. We understand that not all, or 187 perhaps not any, of these methods will be available at all institutions; but we predict that most institutions will 188 have at least one recommended method at their disposal, and collaboration or consultation is advised for those 189 that do not have any recommended method available. We anticipate utilization of these recommended 190 definitions of placental infection by SARS-COV-2 will facilitate comparisons of results amongst studies and 191 that improved interpretation will follow, allowing for maximum impact of research in this area and optimization 192 of patient care. have a positive result due to maternal viremia (although this is a rare entity), rather than placental involvement. 362 1) RT-PCR detection and/or quantification of viral RNA in PBS-rinsed placental homogenates, no 363 tissue localization (validated reagents and sample protocols are summarized in Appendix C). 364 J o u r n a l P r e -p r o o f Note that an alternative approach is a two-step approach, in which RT-PCR is utilized as a screen and then 365 followed up with one of the methods recommended to confirm "definite" or "probable" infection. This 366 hybrid/two-step approach would be more rigorous than RT-PCR alone and potentially more sensitive than the 367 "definite" and "probable" approaches. 368 2) Electron microscopic detection of viral-like particles in placental tissues. 369 UNLIKELY: Negative results from any of the above tests 370 NO TESTING: Placenta not tested 371 372 Table 3 373 Recommended reporting guidelines for scientific manuscripts 374 Scientific manuscripts that report on placental detection of SARS-CoV-2 should report on: 375 1) Sampling method (including location and number of sites sampled) 376 2) Time from delivery to sample preservation 377 3) Method of sample preservation 378 4) Method of detection used (and in the discussion reflect strengths and limitations of that method) 379 Other issues of importance to report: 380 1) The timing of the maternal infection in relationship to the delivery 381 2) Maternal disease severity, recommend using NIH criteria* 382 3) J o u r n a l P r e -p r o o f Characteristics of Women of Reproductive Age with Laboratory SARS-CoV-2 Infection by Pregnancy Status -United States Characteristics and Maternal and Birth Outcomes of Hospitalized 220 Pregnant Women with Laboratory-Confirmed COVID-19 -COVID-NET, 13 States Birth and Infant Outcomes Following Laboratory CoV-2 Infection in Pregnancy -SET-NET, 16 Jurisdictions SARS-CoV-2 RNA-407 ISH is performed using the RNAscope® 2.5 LS Probe-V-nCoV2019-S Cat No. 848568 and RNAscope® 2.5 408 LS Reagent Kit-RED Cat No. 322150 (ACD-Biotechne) . RNA probes include RNAScope, hybridization chain 409 reactions (HCR) designed toward N1/N2/N3 cDNA of SARS-CoV-2 and Human RNase P gene loci on the 410 BOND RX automated staining platform (Leica Biosystems) Protocol to be provided in 412 appendix. RNA-ISH that detects the replication strand is performed with the RNAscope® 2.5 LS Probe-V-413 nCoV2019-S-Sense Probe, Cat No. 845701. RNA-ISH is performed per standard protocol The protocol begins with a one hour 415 incubation at 60C followed by pretreatment using the BOND Epitope Retrieval Solution 2 for 15 min at 95C Signal is amplified by a 417 series of branched DNA amplification steps followed by color development in red using the Bond Polymer 418 Hematoxylin is then perfomed to counterstain the nuclei on the BOND RX 419 machine. Such RNA probes include RNAScope, hybridization chain reactions (HCR) designed toward 420 N1/N2/N3 cDNA of SARS-CoV-2 and Human RNase P gene loci Note that the gold standard of SARS-CoV-2 titer demonstration via plaque assay or TCID50 require a BSL3 422 laboratory setting, which is not achievable in most real-world settings Although the test characteristics for SARS-CoV-2 RNA-ISH in placental samples are not well defined given 425 limited data in these samples, the Ting laboratory has performed a paired analysis of the CDC approved RT-426 qPCR assay and the RNA-ISH in a variety of human autopsy materials from patients who died from COVID-19 427 52 Appropriate positive control should be a FFPE specimen that is from an individual confirmed to be positive for 433 SARS-CoV-2 by RT-PCR and/or RNA-seq AND show positive signal by RNA-ISH in the appropriate tissues Appropriate negative control should be a similar FFPE specimen that is confirmed to be negative for SARS-435 Appropriate positive controls include: 1) infected lung tissues from patients who died of 436 Controls should be performed on each lot of RNA-ISH reagents and on each batch run of cases An example image of of RNA-ISH performed using the above technique is provided as Figure 3 The following antibodies have been validated for immunohistochemistry (IHC) in formalin-fixed paraffin-446 embedded (FFPE) tissue sections: (1) a rabbit polyclonal antibody raised against the nucleocapsid protein and (3) a mouse monoclonal antibody raised against the S2 subunit of the spike protein 451 antibody-1A9/GTX632604) but such studies on tissue sections using brightfield IHC are lacking. IHC using 452 these antibodies requires careful validation for optimal detection and to avoid non-specific and background 453 staining. For analytic validation of IHC laboratory 456 the rationale for that decision should be documented (4). The IHC expert in this consensus group (JLH) utilized 457 infected lung tissues from patients who died of COVID-19 (autopsy cases) as positive controls; negative control 458 cases should include tissues with similar pathologic processes (e.g., diffuse alveolar damage in the lung). The 459 appropriate placental negative control in this context would be one with chronic histiocytic intervillositis and/or 460 massive perivillous fibrin deposition at a similar gestational age Hornick's laboratory at the Brigham and Women's Hospital, Boston, MA, IHC was performed following 462 pressure cooker antigen retrieval (pH 6.1 citrate buffer; Target Retrieval Solution, Dako) using the anti-spike An example image of of placental Spike IHC performed using the above technique is provided as Figure 4 Assessment of SARS CoV-2 RNA was performed using Superscript III one step RT-PCR system with dNTP) and 3.2 mM magnesium sulfate), 1 μl of reverse transcriptase/Taq 471 mixture from the kit, 0.4 μl of a 50 mM magnesium sulfate solution (Invitrogen -not provided 472 with the kit), and 1 μg of nonacetylated bovine serum albumin (Roche RNaseP, should be used to validate the extraction of RNA from the specimen We recommend a Ct cutoff of <40 for the limit of detection 483 of 50 copies/ml. The use of semi-quantitative methods such as inferring viral burden from Ct values should 484 be confirmed by assessing infectious virions from the specimen (Vero E6 culture). The most rigorous approach 485 is quantitative RT-qPCR, where a standard curve of RNA is generated for quantifying viral load using a CDC 486 positive control. For quantitative RT-qPCR, SARS-CoV-2 viral loads below 40 RNA copies/mL should 487 be categorized as undetectable and set at 1.0 log10 RNA copies/mL. Positive controls are commercially 488 available for several SARS-CoV-2 target genes Of note, while respiratory and serum or plasma viral load have been demonstrated 490 to correlate with disease severity and death in a cohort of non-pregnant older adults 54 , available data suggest 491 that viremia is rare in pregnancy 29 , and there is a lack of data regarding placental viral load and increased risk 492 of adverse obstetrical or neonatal outcomes, including but not limited to vertical transmission. Regardless, 493 quantitative methods are recommended over semi-quantitative or binary (positive/negative) methods, both 494 because of their increased rigor